Leadership change for German Merck
German pharma, science and technology company Merck KGAA (MRK: DE) today announced that Rehan Verjee has made the decision to leave his position as president of its EMD Serono unit and global head of innovative medicine franchises, to pursue an opportunity outside of Merck that will soon be announced.
He will be succeeded by Andrew Paterson, who is currently senior vice president and head of both the global multiple sclerosis (MS) franchise and the MS business unit in the USA. Mr Paterson will be based in Rockland, Massachusetts, USA, and will serve as a member of the Healthcare Executive Committee.
“Rehan has had a significant impact on the business of Merck and on the lives of patients during his 17-year tenure at the company, which have included five years as a valued member of the healthcare executive team,” said Peter Guenter, a member of the executive board of Merck and chief executive Healthcare. “
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze